Stocks · News reference
Mizuho analyst Anthony Petrone maintains ADMA Biologics (NASDAQ:ADMA) with a Outperform and lowers the price target from $20 to $17.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
ADMA Biologics (NASDAQ:ADMA) affirms FY2026 sales outlook from $530.000 million-$560.000 million to $530.000 million-$560.000 million vs $559.495 million estimate.
Read original at benzingaADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.16 per share which missed the analyst consensus estimate of $0.17 by 5.88 percent. This is a 14.29 percent increase over earnings of $0.14 per share from
Read original at benzingaFiled: 2026-08-05 AccNo: 0001140361-26-031423 Size: 704 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarKahn Swick & Foti, LLC announces a class action securities lawsuit against ADMA Biologics, Inc. for investors who purchased securities between August 9, 2024 and March 25, 2026. The lawsuit alleges the company and its executives failed to disclose material information, including undisclosed related party transactions, channel stuffing, and inadequate internal controls. The application deadline to request lead plaintiff status is August 10, 2026.
Read original at globenewswire-inc